CONGRESS: 22–25 SEPTEMBER 2025
Cohesive diagnostic ecosystem in the spotlight at IBMS Congress
At IBMS Congress, laboratory and point-of-care (POC) suppliers Radiometer, Cepheid and Leica Biosystems are exhibiting under the Danaher Diagnostics Solutions umbrella to showcase a combined solution to the challenges faced by clinical pathology and POC.
From urgent care scenarios to complex cancer diagnostics, clinicians rely on accurate and timely pathology results to inform treatment plans. However, diagnostic processes are often spread across multiple departments, with separate systems handling acute care, molecular diagnostics, and histopathology. This disjointed approach can delay results, increase risk of errors, and complicate decision-making. Healthcare systems like the NHS are also under pressure to meet national targets – such as the 28-day Faster Diagnosis Standard for cancer, the four-hour A&E standard and improved sepsis management protocols – as well as addressing antimicrobial resistance issues and managing winter pressures. Therefore, integrating workflows into one cohesive diagnostic ecosystem can be advantageous.
Danaher Diagnostic Solutions Under the umbrella of Danaher Diagnostics Solutions, companies including Radiometer, Cepheid, Leica Biosystems and Beckman Coulter aim to achieve this by offering a powerful combined solution to the challenges faced by clinical pathology and POC testing today.
Supporting modern clinical diagnostics At IBMS Congress 2025, these companies will be joining forces on Stand 109 (Radiometer, Cepheid and Leica BioSystems) and Stand 608 (Beckman Coulter), to demonstrate the Danaher Diagnostics Solutions portfolio, which collectively supports millions of diagnostic tests every day across hospitals, laboratories, and POC settings worldwide, offering molecular, pathology, immunoassay, haematology, and critical care testing. Collectively, they will be demonstrating their natural synergies and showcase how their individual platforms are able to
46
Leica Biosystems.
integrate through: n shared connectivity n data insights n service models n enabling streamlined end-to-end diagnostic workflows
n POC testing to rapid molecular and tissue analysis.
The companies’ goal is to create a connected diagnostic ecosystem - one that brings together each company’s collective strengths to address some of the most urgent challenges faced by providers in healthcare today, advancing precision medicine for future generations of patients.
Cepheid. AUGUST 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
